Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive TuberculosisStephen H. Gillespie, Andrew Nunn|New England Journal of Medicine|2014Cited by 653
Perspective for Precision Medicine for TuberculosisChristoph Lange, Andrew R. DiNardo, Rob E. Aarnoutse et al.|Frontiers in Immunology|2020Cited by 69
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBConor Tweed, Stephen H. Gillespie, Matt Betteridge et al.|The International Journal of Tuberculosis and Lung Disease|2021Cited by 63